133 related articles for article (PubMed ID: 38175892)
1. Microbiota-dependent activation of CD4
Lo BC; Kryczek I; Yu J; Vatan L; Caruso R; Matsumoto M; Sato Y; Shaw MH; Inohara N; Xie Y; Lei YL; Zou W; Núñez G
Science; 2024 Jan; 383(6678):62-70. PubMed ID: 38175892
[TBL] [Abstract][Full Text] [Related]
2. The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology.
Zhang S; Liang W; Luo L; Sun S; Wang F
BMC Biol; 2020 Mar; 18(1):29. PubMed ID: 32183814
[TBL] [Abstract][Full Text] [Related]
3. Probiotics
Wang T; Zheng N; Luo Q; Jiang L; He B; Yuan X; Shen L
Front Immunol; 2019; 10():1235. PubMed ID: 31214189
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Luoma AM; Suo S; Williams HL; Sharova T; Sullivan K; Manos M; Bowling P; Hodi FS; Rahma O; Sullivan RJ; Boland GM; Nowak JA; Dougan SK; Dougan M; Yuan GC; Wucherpfennig KW
Cell; 2020 Aug; 182(3):655-671.e22. PubMed ID: 32603654
[TBL] [Abstract][Full Text] [Related]
5. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
6. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
[TBL] [Abstract][Full Text] [Related]
7. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.
Coutzac C; Adam J; Soularue E; Collins M; Racine A; Mussini C; Boselli L; Kamsukom N; Mateus C; Charrier M; Cassard L; Planchard D; Ribrag V; Fizazi K; Loriot Y; Lepage P; Scoazec JY; Robert C; Carbonnel F; Chaput N
J Crohns Colitis; 2017 Oct; 11(10):1238-1246. PubMed ID: 28967957
[TBL] [Abstract][Full Text] [Related]
8. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
[TBL] [Abstract][Full Text] [Related]
9. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
10. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
11. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
Belcaid Z; Phallen JA; Zeng J; See AP; Mathios D; Gottschalk C; Nicholas S; Kellett M; Ruzevick J; Jackson C; Albesiano E; Durham NM; Ye X; Tran PT; Tyler B; Wong JW; Brem H; Pardoll DM; Drake CG; Lim M
PLoS One; 2014; 9(7):e101764. PubMed ID: 25013914
[TBL] [Abstract][Full Text] [Related]
12. Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events.
Müller B; Bärenwaldt A; Herzig P; Zippelius A; Maul LV; Hess V; König D; Läubli H
Front Immunol; 2023; 14():1125111. PubMed ID: 37122748
[TBL] [Abstract][Full Text] [Related]
13.
Sun S; Luo L; Liang W; Yin Q; Guo J; Rush AM; Lv Z; Liang Q; Fischbach MA; Sonnenburg JL; Dodd D; Davis MM; Wang F
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27509-27515. PubMed ID: 33077598
[TBL] [Abstract][Full Text] [Related]
14. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
[TBL] [Abstract][Full Text] [Related]
15.
Wang F; Yin Q; Chen L; Davis MM
Proc Natl Acad Sci U S A; 2018 Jan; 115(1):157-161. PubMed ID: 29255057
[TBL] [Abstract][Full Text] [Related]
16. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
17. Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events.
Tsukamoto H; Komohara Y; Tomita Y; Miura Y; Motoshima T; Imamura K; Kimura T; Ikeda T; Fujiwara Y; Yano H; Kamba T; Sakagami T; Oshiumi H
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2205378119. PubMed ID: 35858347
[TBL] [Abstract][Full Text] [Related]
18. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack MH; Betof A; Dearden H; Rapazzo K; Valentine I; Brohl AS; Ancell KK; Long GV; Menzies AM; Eroglu Z; Johnson DB; Shoushtari AN
Ann Oncol; 2018 Jan; 29(1):250-255. PubMed ID: 29045547
[TBL] [Abstract][Full Text] [Related]
19. Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults.
Arra A; Pech M; Fu H; Lingel H; Braun F; Beyer C; Spiliopoulou M; Bröker BM; Lampe K; Arens C; Vogel K; Pierau M; Brunner-Weinzierl MC
Oncoimmunology; 2021 Jun; 10(1):1938475. PubMed ID: 34178430
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.
McCoy KD; Hermans IF; Fraser JH; Le Gros G; Ronchese F
J Exp Med; 1999 Apr; 189(7):1157-62. PubMed ID: 10190907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
